Display options
Cite
Eo WK, Kwon S, Koh SB, et al. The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer. J Cancer. 2016;7(5):538-45doi: 10.7150/jca.14206.
Eo, W. K., Kwon, S., Koh, S. B., Kim, M. J., Ji, Y. I., Lee, J. Y., Suh, D. S., Kim, K. H., & Kim, H. Y. (2016). The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer. Journal of Cancer, 7(5), 538-45. https://doi.org/10.7150/jca.14206
Eo, Wan Kyu, et al. "The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer." Journal of Cancer vol. 7,5 (2016): 538-45. doi: https://doi.org/10.7150/jca.14206
Eo WK, Kwon S, Koh SB, Kim MJ, Ji YI, Lee JY, Suh DS, Kim KH, Kim HY. The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer. J Cancer. 2016 Feb 20;7(5):538-45. doi: 10.7150/jca.14206. eCollection 2016. PMID: 27053952; PMCID: PMC4820730.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2016 Feb 20;7(5):538-45. doi: 10.7150/jca.14206. eCollection 2016.

The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer.

Journal of Cancer

Wan Kyu Eo, Sanghoon Kwon, Suk Bong Koh, Min Jeong Kim, Yong Il Ji, Ji Young Lee, Dong Soo Suh, Ki Hyung Kim, Heung Yeol Kim

Affiliations

  1. 1. Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
  2. 2. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea.
  3. 3. Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, Daegu, Korea.
  4. 4. Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, Korea.
  5. 5. Department of Obstetrics and Gynecology, College of Medicine, Inje University, Busan, Korea.
  6. 6. Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
  7. 7. Department of Obstetrics and Gynecology, Pusan National University School of Medicine; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  8. 8. Department of Obstetrics and Gynecology, College of Medicine, Kosin University, Busan, Korea.

PMID: 27053952 PMCID: PMC4820730 DOI: 10.7150/jca.14206

Abstract

OBJECTIVE: We assessed the prognostic implications of preoperative lymphocyte-monocyte ratio (LMR) in patients with endometrial cancer (EC).

METHODS: We retrospectively examined the LMR as a prognostic variable in a cohort of 255 patients with EC who underwent surgical resection. Patients were categorized into two groups according to the LMR (LMR-low and LMR-high) using cutoff points determined by receiving operator characteristic (ROC) curve analysis. The primary objective was to correlate the LMR to clinicopathological factors; the secondary objective was to determine the survival significance of the LMR in patients with EC.

RESULTS: Using data from the entire cohort, the most discriminative LMR cutoff value selected on the ROC curve was 3.28 for both disease-free survival (DFS) and overall survival (OS). The LMR-low and LMR-high groups included 33 (12.9%) and 222 patients (87.1%), respectively. The 5-year DFS rates in the LMR-low and LMR-high groups were 64.5 and 93.9% (P < 0.0001), respectively, and the 5-year OS rates in the two groups were 76.7 and 96.5% (P < 0.0001), respectively. On multivariate analysis, we identified histologic grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and LMR levels as the strongest prognostic factors affecting DFS (P = 0.0037, P < 0.0001, and P < 0.0001, respectively), and FIGO stage and the LMR as the strongest prognostic factors predicting OS (P < 0.0001 and P < 0.0001, respectively).

CONCLUSION: The LMR is an independent prognostic factor for both DFS and OS after surgical resection, and it provides additional prognostic value beyond standard clinicopathological parameters.

Keywords: Endometrial Cancer; Lymphocytes; Monocytes

References

  1. Onco Targets Ther. 2015 Jun 08;8:1355-62 - PubMed
  2. Ann Hematol. 2015 Oct;94(10):1645-54 - PubMed
  3. Br J Cancer. 2015 Jul 14;113(2):311-20 - PubMed
  4. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):489-97 - PubMed
  5. Obstet Gynecol. 1996 Aug;88(2):280-2 - PubMed
  6. Gynecol Oncol. 2015 Aug;138(2):332-8 - PubMed
  7. Gynecol Oncol. 2014 Mar;132(3):542-50 - PubMed
  8. Int J Gynecol Cancer. 2009 Nov;19(8):1384-9 - PubMed
  9. Obstet Gynecol. 2010 Nov;116(5):1141-9 - PubMed
  10. PLoS One. 2015 Jun 24;10(6):e0130640 - PubMed
  11. Gynecol Oncol. 1991 Jan;40(1):55-65 - PubMed
  12. Gynecol Oncol. 2015 Apr;137(1):112-8 - PubMed
  13. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 - PubMed
  14. Pancreatology. 2015 Mar-Apr;15(2):145-50 - PubMed
  15. Cell. 2010 Mar 19;140(6):883-99 - PubMed
  16. Int J Gynecol Cancer. 2010 Jul;20(5):745-50 - PubMed
  17. Anticancer Res. 2015 Jan;35(1):337-43 - PubMed
  18. Gan To Kagaku Ryoho. 2006 Nov;33(11):1595-602 - PubMed
  19. Gynecol Oncol. 1982 Jun;13(3):373-92 - PubMed
  20. Nature. 2002 Dec 19-26;420(6917):860-7 - PubMed
  21. Int J Gynecol Cancer. 2013 Feb;23(2):304-11 - PubMed
  22. J Transl Med. 2015 Feb 18;13:66 - PubMed
  23. Am J Obstet Gynecol. 2008 Feb;198(2):216.e1-5 - PubMed
  24. PLoS One. 2012;7(7):e41658 - PubMed
  25. Clin Chem Lab Med. 2015 Feb;53(3):499-506 - PubMed
  26. Methods Mol Biol. 2009;512:325-32 - PubMed
  27. PLoS One. 2013 Dec 27;8(12):e83069 - PubMed
  28. J Immunol Res. 2014;2014:349546 - PubMed
  29. Br J Cancer. 2014 Jan 21;110(2):435-40 - PubMed
  30. Eur J Obstet Gynecol Reprod Biol. 2012 Jun;162(2):206-10 - PubMed
  31. Int J Gynaecol Obstet. 2009 May;105(2):103-4 - PubMed
  32. Onco Targets Ther. 2015 Jan 08;8:137-45 - PubMed
  33. BMC Cancer. 2013 May 03;13:222 - PubMed
  34. Tumour Biol. 2015 Nov;36(11):8537-43 - PubMed
  35. Chin J Cancer. 2015 Jun 10;34(6):237-46 - PubMed
  36. J Gynecol Oncol. 2012 Oct;23(4):265-73 - PubMed
  37. Gynecol Oncol. 2015 Sep;138(3):614-9 - PubMed
  38. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  39. Lancet. 2001 Feb 17;357(9255):539-45 - PubMed
  40. Tumour Biol. 2014 Nov;35(11):11659-66 - PubMed
  41. J Surg Res. 2015 Dec;199(2):386-92 - PubMed
  42. Nat Rev Cancer. 2004 Jan;4(1):71-8 - PubMed
  43. Gynecol Oncol. 2012 Jan;124(1):31-5 - PubMed
  44. Med Oncol. 2014 Jul;31(7):70 - PubMed
  45. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):21-7 - PubMed
  46. Onco Targets Ther. 2013;6:211-6 - PubMed
  47. J Cancer Res Clin Oncol. 2009 Jan;135(1):125-9 - PubMed
  48. Cancer. 1985 Apr 15;55(8):1753-7 - PubMed
  49. Asian Pac J Cancer Prev. 2015;16(13):5305-10 - PubMed
  50. PLoS One. 2014 Nov 05;9(11):e111886 - PubMed
  51. Med Oncol. 2014 Dec;31(12):323 - PubMed
  52. Nat Rev Immunol. 2011 Oct 10;11(11):762-74 - PubMed
  53. Int J Gynecol Cancer. 2015 Oct;25(8):1453-60 - PubMed
  54. Eur J Surg Oncol. 2013 Apr;39(4):350-7 - PubMed
  55. Tex Heart Inst J. 2013;40(1):17-29 - PubMed
  56. Nature. 2008 Jul 24;454(7203):436-44 - PubMed
  57. PLoS One. 2014 Oct 02;9(9):e108062 - PubMed
  58. Tumour Biol. 2014 Nov;35(11):10849-54 - PubMed
  59. Asian Pac J Cancer Prev. 2015;16(6):2245-50 - PubMed
  60. Lancet. 2012 Apr 7;379(9823):1352-60 - PubMed
  61. BMC Cancer. 2014 May 19;14:341 - PubMed
  62. Asian Pac J Cancer Prev. 2014;15(23):10231-6 - PubMed

Publication Types